Haemonetics Acquires Vivasure Medical for €100M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Haemonetics announced the acquisition of Vivasure Medical. The acquisition includes an upfront cash payment of EUR 100M, or approximately EUR 52M net of the value of certain previous investments and other loans made by Haemonetics to Vivasure as well as other customary closing adjustments, and up to an additional EUR 85M in contingent consideration based on sales growth and the achievement of certain other milestones, also subject to adjustment based on the value of certain prior investments and loan amounts. Haemonetics financed this transaction through available cash on hand.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 88.86 USD with a low forecast of 74.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
